Bedalov A, Chowdhury S, Simon J A
Fred Hutchinson Cancer Research Center, Seattle, WA, United States.
Fred Hutchinson Cancer Research Center, Seattle, WA, United States.
Methods Enzymol. 2016;574:183-211. doi: 10.1016/bs.mie.2016.03.011. Epub 2016 Mar 28.
Sirtuins are a family of protein deacylases related by amino acid sequence and cellular function to the yeast Saccharomyces cerevisiae protein Sir2 (Silent Information Regulator-2), the first of this class of enzymes to be identified and studied in detail. Based on its initially discovered activity, Sir2 was classified as a histone deacetylase that removes acetyl groups from histones H3 and H4. The acetylation/deacetylation of these particular substrates leads to changes in transcriptional silencing at specific loci in the yeast genome, hence its name. Sirtuins, however, have been shown to regulate a wide variety of cellular processes beyond transcriptional repression in varied subcellular compartments and in different cell types. Mechanistically distinct from Zn(2+)-dependent deacylases, sirtuins use nicotinamide adenine dinucleotide as a cofactor in the removal of acetyl and other acyl groups linking metabolic status and posttranslational modification. Sirtuins' unique position has made them attractive targets for small-molecule drug development. In this chapter, we describe the biological roles, therapeutic areas in which sirtuins may play a role and development of small-molecule inhibitors of sirtuins employing phenotypic screening technologies ranging from assays in yeast, as well as biochemical screens to yield lead drug development candidates targeting a broad spectrum of human diseases.
沉默调节蛋白是一类蛋白质脱酰酶家族,其氨基酸序列和细胞功能与酿酒酵母蛋白Sir2(沉默信息调节因子2)相关,Sir2是这类酶中第一个被鉴定并详细研究的。基于其最初发现的活性,Sir2被归类为一种组蛋白脱乙酰酶,可从组蛋白H3和H4上去除乙酰基。这些特定底物的乙酰化/去乙酰化导致酵母基因组中特定基因座的转录沉默发生变化,因此得名。然而,沉默调节蛋白已被证明可在不同的亚细胞区室和不同细胞类型中调节转录抑制以外的多种细胞过程。与依赖锌离子的脱酰酶在机制上不同,沉默调节蛋白在去除连接代谢状态和翻译后修饰的乙酰基和其他酰基时使用烟酰胺腺嘌呤二核苷酸作为辅助因子。沉默调节蛋白的独特地位使其成为小分子药物开发的有吸引力的靶点。在本章中,我们描述了沉默调节蛋白的生物学作用、可能发挥作用的治疗领域,以及采用从酵母试验到生化筛选等表型筛选技术开发沉默调节蛋白小分子抑制剂的情况,以产生针对广泛人类疾病的先导药物开发候选物。